Latest News

Evidence mounting that full-body emollients don’t prevent AD in at-risk babies

Publish date: October 24, 2022

 

AT ISAD 2022

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Topical ruxolitinib quickly relieves atopic dermatitis itch in Black patients
MDedge Pediatrics
Vitamin D supplements during pregnancy may protect infants from atopic eczema
MDedge Pediatrics
VTE risk not elevated in AD patients on JAK inhibitors: Study
MDedge Pediatrics
Roflumilast foam effectively eases seborrheic dermatitis
MDedge Pediatrics
Tralokinumab earns EU recommendation to expand age range for atopic dermatitis to include adolescents
MDedge Pediatrics
Early emollient use reduces dermatitis in at-risk infants
MDedge Pediatrics
Study identifies skin biomarkers that predict newborn eczema risk
MDedge Pediatrics
BREEZE-AD-PEDS: First data for baricitinib in childhood eczema reported
MDedge Pediatrics
Dupilumab study outlines benefits, safety profile in infants, preschoolers with atopic dermatitis
MDedge Pediatrics
Dermatologists fear effects of Dobbs decision for patients on isotretinoin, methotrexate
MDedge Pediatrics